{"id":"W2622249265","doi":"10.1200/jco.2017.35.15_suppl.1038","title":"Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Medicine; Letrozole; Clinical endpoint; Progression-free survival; Internal medicine; Interim analysis; Breast cancer; Cancer; Oncology; Gynecology; Surgery; Clinical trial; Chemotherapy; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002551384,0.000385265,0.003284866,0.0002118796,0.0001467044,0.00001939773,0.000609776,0.0006387401,0.0003711846],"category_scores_gemma":[0.006399938,0.0003038553,0.0006853683,0.000224197,0.001046905,0.0005913508,0.0001576948,0.001890537,0.00001355032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006591093,"about_ca_system_score_gemma":0.001665792,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001682712,"about_ca_topic_score_gemma":0.001843817,"domain_scores_codex":[0.9930441,0.0006318178,0.004568368,0.000548163,0.0007155026,0.0004920851],"domain_scores_gemma":[0.9864713,0.00304859,0.007893722,0.0007115545,0.001346564,0.0005282951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7065898,0.006002137,0.005051704,0.00001326532,0.001031263,0.0004636919,0.0004917422,0.0001899704,0.001957858,0.00001219311,0.001078551,0.2771178],"study_design_scores_gemma":[0.6779444,0.03216398,0.2521625,0.0009988614,0.000585327,0.0001305484,0.0004510679,0.0003329001,0.002338408,0.001184966,0.0313055,0.0004015374],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9654848,0.0008416828,0.0001728349,0.02878713,0.001961704,0.0007914337,0.001101314,0.00001778762,0.0008413428],"genre_scores_gemma":[0.9865843,0.003445434,0.005470683,0.0008140694,0.003242832,0.00003138653,0.00005925504,0.00005553894,0.0002964847],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2767163,"threshold_uncertainty_score":0.9999413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07992102643971791,"score_gpt":0.4703164477870385,"score_spread":0.3903954213473206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}